万孚生物 reported revenue of ¥1.04B for the period ended 2026-06-30, -16.6% year on year. Net income was ¥0.13B, a 12.1% net margin on a 63.5% gross margin. The largest revenue line is 慢性疾病检测 at 48% of the total. Free cash flow for the period was ¥0.16B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.04B | -16.6% |
| Gross profit | ¥0.66B | — |
| Operating income | ¥0.14B | — |
| Net income | ¥0.13B | -34.2% |
| Gross margin | 63.5% | Net margin 12.1% |
| Revenue Q/Q | -21.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 慢性疾病检测 | ¥0.50B | 47.8% |
| 传染病检测 | ¥0.26B | 24.8% |
| 毒品(药物滥用)检测 | ¥0.13B | 12.5% |
| 妊娠及优生优育检测 | ¥0.12B | 11.3% |
| 其他主营业务 | ¥0.03B | 3.2% |
| 其他(补充) | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 36.5% |
| R&D | ¥0.14B | 13.3% |
| SG&A | ¥0.36B | 34.4% |
| Tax & other | ¥0.02B | 1.7% |
| Item | Amount |
|---|---|
| Total assets | ¥6.74B |
| Total liabilities | ¥1.23B |
| Shareholders' equity | ¥5.51B |
| Equity / assets | 81.7% |
| Operating cash flow | ¥0.21B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.16B |
| Cash conversion (OCF / net income) | 339% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
首华燃气 ・ 蓝海华腾 ・ 赛升药业 ・ 东杰智能 ・ 蓝晓科技 ・ 恒锋工具 ・ 光智科技 ・ 华自科技 ・ 通合科技 ・ 华图山鼎 ・ 润欣科技 ・ 盛天网络
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies